IgA Nephropathy

A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.

Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.

Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.

Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.

Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.

An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.

Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.

The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.

We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.

Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).

Knowledge Hubs